Literature DB >> 35427203

Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia.

Martin Andersen1, Anurag Pant1.   

Abstract

BACKGROUND: Utilization management policies are pervasive in the Medicare Part D program. We assess the effect of utilization management restrictions in the Medicare Part D program on the quality of care in two clinical areas - community-acquired pneumonia (CAP) and urinary tract infections (UTI).
METHODS: In this study, we identified new cases of CAP and UTI from Medicare claims data from 2010 to 2016. We assessed the relationship between exposure to utilization management for antibiotic medications suitable for treating these conditions and adverse health outcomes, based on the Agency for Healthcare Research and Quality prevention quality indicators.
RESULTS: We identified 147,526 cases of CAP and 632,407 UTI cases in our data. In these samples, the adverse event rate varied from 3.6 to 5.7%. The probability of an adverse event increased by 0.75 (p = 0.061) percentage points for each ten percentage point increase in exposure to quantity limits (one form of utilization management) among people with CAP. There was no relationship between utilization management and adverse events in the UTI cohort.
CONCLUSIONS: In some circumstances, exposure to utilization management policies-particularly quantity limits-may adversely affect health.

Entities:  

Keywords:  Antibiotic prescribing; pneumonia; urinary tract infections; utilization management

Mesh:

Substances:

Year:  2022        PMID: 35427203      PMCID: PMC9463087          DOI: 10.1080/14737167.2022.2067529

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.039


  18 in total

1.  Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.

Authors:  William B Vogt; Geoffrey Joyce; Jing Xia; Riad Dirani; George Wan; Dana P Goldman
Journal:  Health Aff (Millwood)       Date:  2011-12       Impact factor: 6.301

2.  Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.

Authors:  Mark Duggan; Patrick Healy; Fiona Scott Morton
Journal:  J Econ Perspect       Date:  2008

3.  The impact of Medicare Part D on hospitalization rates.

Authors:  Christopher C Afendulis; Yulei He; Alan M Zaslavsky; Michael E Chernew
Journal:  Health Serv Res       Date:  2011-02-09       Impact factor: 3.402

4.  The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics.

Authors:  Ernst R Berndt; Robert S Gibbons; Anton Kolotilin; Anna Levine Taub
Journal:  J Health Econ       Date:  2014-12-12       Impact factor: 3.883

5.  The Effects of Medicare Part D on Health Outcomes of Newly Covered Medicare Beneficiaries.

Authors:  Jeffrey Diebold
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2018-06-14       Impact factor: 4.077

6.  Paying Attention or Paying Too Much in Medicare Part D.

Authors:  Jonathan D Ketcham; Claudio Lucarelli; Christopher A Powers
Journal:  Am Econ Rev       Date:  2015-01

7.  Patient Cost-Sharing and Hospitalization Offsets in the Elderly.

Authors:  Amitabh Chandra; Jonathan Gruber; Robin McKnight
Journal:  Am Econ Rev       Date:  2010-03-01

8.  The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.

Authors:  Yujin Park; Syed Raza; Aneesh George; Rumjhum Agrawal; John Ko
Journal:  J Manag Care Spec Pharm       Date:  2017-08

9.  Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

Authors:  Stephen B Soumerai; Fang Zhang; Dennis Ross-Degnan; Daniel E Ball; Robert F LeCates; Michael R Law; Tom E Hughes; Daniel Chapman; Alyce S Adams
Journal:  Health Aff (Millwood)       Date:  2008-04-01       Impact factor: 6.301

10.  Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications.

Authors:  Qamar Niaz; Brian Godman; Stephen Campbell; Dan Kibuule
Journal:  Int J Clin Pharm       Date:  2020-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.